Theradiag, Marne-La-Vallée, France, has launched the BioCLIA 1 200, a fourth?generation automated diagnostic system that harnesses the latest chemiluminescence technology based on nanoparticles. The random access system can simultaneously manage several types of analysis, and delivers results in less than an hour. It offers a diversified immunoassay menu for allergy, autoimmunity, and biotherapy monitoring.
Under a cross-distribution agreement, the system is being launched as a codeveloped product with HOB Biotech, Beijing. The companies are codeveloping a full portfolio of allergy, autoimmunity, and biotherapy monitoring reagents, which are scheduled for introduction gradually from 2017 onward. Theradiag is the exclusive distributor of the BioCLIA instrument in Europe.
Michel Finance, Theradiag.
“The BioCLIA 1 200 will reenergize our longstanding activities, especially in autoimmunity, our core area of expertise,” says Michel Finance, chief executive of Theradiag. “With the future commercialization of autoimmune, allergy, and theranostic diagnostics, Theradiag is accelerating the development of its in vitro diagnostics business unit as part of its drive for robust global growth. The codevelopment partnership with HOB Biotech will enable us to rapidly bring to market a solution offering our customers the best cost/benefit performance.”
For more information, visit Theradiag.
